Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL29010960 | 0.92 | POLB (0.39) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| Sulfuric Acid SCHEMBL8846690 | 0.92 | POLB (0.42) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| SCHEMBL28790654 | 0.90 | POLB (0.38) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| SCHEMBL83682 | 0.90 | POLB (0.38) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| SCHEMBL27719314 | 0.90 | HSD17B10 (0.37) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL28378505 | 0.89 | SMN1; SMN2 (0.37) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| Ammonia Solution, Strong SCHEMBL28018788 | 0.89 | POLB (0.37) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| SCHEMBL6010040 | 0.89 | POLB (0.37) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| Alcohol SCHEMBL28979374 | 0.89 | POLB (0.37) | HSD17B10KMT2AMEN1CHRM5CHRM3 | |
| Sulfuric Acid SCHEMBL28627994 | 0.88 | POLB (0.39) | HSD17B10KMT2AMEN1CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112351821-A | Composition comprising a saturated fatty alcohol, at least one fatty chain anionic surfactant, a polyol and at least one silicone oil | 莱雅公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-102558231-B | Ophthalmic compositions for treating ocular hypertension | MERCK & CO INC | 2015-05-27 | — | — | CN | disclosed |
| CN-102558231-A | Ophthalmic compositions for treating ocular hypertension | MERCK & CO INC | 2012-07-11 | — | — | CN | disclosed |
| US-7563816-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1771170-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1802300-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1663221-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009048558-A1 | MAXI-K CHANNEL BLOCKERS AND METHODS OF USE | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048559-A1 | MAXI-K CHANNEL BLOCKERS AND METHODS OF USE | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-1663987-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1487438-A2 | COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004087051-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003105724-A2 | NOVEL MAXI-K CHANNEL BLOCKERS, METHODS OF USE AND PROCESS FOR MAKING THE SAME | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105868-A1 | NOVEL MAXI-K CHANNEL BLOCKERS, METHODS OF USE AND PROCESS FOR MAKING THE SAME | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105847-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030191173-A1 | Method for treating ocular hypertension | GARCIA MARIA L (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2003077845-A2 | COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-6548535-B2 | Administering indole diterpene compounds as potent potassium channel blockers | MERCK & CO., INC. | 2003-04-15 | — | — | US | disclosed |
| US-20010047025-A1 | Method for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047025-A1 | Method for treating ocular hypertension | KCNH3, HCN1, KCNH2 | HSD17B10 1994/4885KMT2A 2281/4885MEN1 1356/4885 |
| US-20030191173-A1 | Method for treating ocular hypertension | KCNH3, HCN1, KCNH2 | HSD17B10 1994/4885KMT2A 2281/4885MEN1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.